Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Perrigo (NY:PRGO)

13.64 -0.14 (-1.02%)
Streaming Delayed Price Updated: 11:15 AM EST, Nov 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Perrigo

< Previous 1 2 3 4 5 Next >
News headline image
Securities Fraud Investigation Into Perrigo Company plc (PRGO) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
Perrigo Company plc (PRGO) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Perrigo Company plc (PRGO) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
Why Did Perrigo Stock Tumble 9% Pre-Market Today? ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 5, 2025 ↗
 
Via Benzinga
News headline image
What Does the Market Think About Perrigo? ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Perrigo (PRGO) Q3 2025 Earnings Call Transcript ↗
Perrigo (PRGO) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Perrigo (NYSE:PRGO) Posts Mixed Q3 2025 Results with EPS Beat and Revenue Miss ↗
Perrigo's Q3 2025 results show an earnings beat but a revenue miss. The stock dipped as the company announced a strategic review of its infant formula business. 
Via Chartmill
Topics Earnings
News headline image
DRZ Investment Advisors Initiated a Position in KB Home. Is the Stock a Buy? ↗
Via The Motley Fool
News headline image
Earnings Scheduled For August 6, 2025 ↗
 
Via Benzinga
News headline image
A Peek at Perrigo's Future Earnings ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 7, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2025 ↗
 
Via Benzinga
News headline image
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields ↗
 
Via Benzinga
News headline image
Is the Market Bullish or Bearish on Perrigo Co PLC? ↗
 
Via Benzinga
News headline image
Trump's New Tariff Barrage Targets Drugs, Trucks, Cabinets: President Says Move Will Protect Manufacturers From 'Unfair Outside Competition' ↗
President Donald Trump announced a barrage of new tariffs on Thursday, aimed at pharmaceuticals, heavy trucks and home furnishings in particular, to shore up domestic industry in these sectors, and... 
Via Benzinga
Topics Government World Trade
News headline image
Missed Opt-Out Deadline Could Cost Investors Millions In Perrigo Fraud Suit ↗
Perrigo faces a legal battle over whether major investor Sculptor can exit a securities class action years after missing the opt-out deadline amid $1 billion restatements. 
Via Benzinga
Topics Fraud
News headline image
Perrigo (PRGO) Q2 EPS Rises 7.5% ↗
Via The Motley Fool
Topics Earnings Economy Supply Chain
News headline image
Perrigo Co PLC (NYSE:PRGO) Q2 2025 Earnings Miss Estimates, Shares Drop 6% in Pre-Market Trading ↗
Perrigo's Q2 2025 earnings missed revenue and EPS estimates, causing a 6% pre-market drop. Strategic initiatives like divestments and global growth were overshadowed by weak results. 
Via Chartmill
Topics Earnings
News headline image
These 3 Dividend Stocks Combine Strong Yields With Upside
These three high-yield dividend stocks are well-positioned to deliver a strong return, making them attractive to both income and growth-oriented investors 
Via MarketBeat
Topics World Trade
News headline image
Trump Tariffs Could Have 'Significant Impact' On Perrigo Earnings, Says JP Morgan ↗
JP Morgan warns tariffs could impact Perrigo's near-term earnings, though efficiencies and price hikes may ease pressure by 2026. 
Via Benzinga
Topics Government World Trade
News headline image
Nasdaq, S&P 500 Head for Worst Weekly Losses Since September ↗
Stocks are higher midday, getting a much-needed lift from this morning's inflation data that came in line with estimates. 
Via Talk Markets
Topics Economy Stocks Stocks / Equities
News headline image
Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027 ↗
Perrigo Company shares surged after issuing financial targets for 2025 & 2025-2027 on investor day. Expect sales growth, EPS, and margin expansion. 'Three-S' plan will enhance cash flow & shareholder... 
Via Benzinga
News headline image
These stocks are gapping in today's session ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday. 
Via Chartmill
News headline image
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
News headline image
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability ↗
JP Morgan assesses the specialty pharma sector, highlighting robust fundamentals and new product excitement. Key focus on Teva, Organon, and Viatris. 
Via Benzinga
News headline image
PRGO Stock Earnings: Perrigo Beats EPS, Misses Revenue for Q2 2024 ↗
PRGO stock results show that Perrigo beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Abbott Labs (ABT) Stock Falls on Baby Formula Ruling. What to Know. ↗
ABT stock is in focus on ruling news. Abbott faced a suit last year over the closing of its Michigan plant resulting in a formula shortage. 
Via InvestorPlace
News headline image
AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case ↗
AbbVie petitions the U.S. Supreme Court to protect its corporate records, arguing a lower court ruling threatens attorney-client privilege. 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.